Additionally, the beneficial effect of EPs on HFD-induced colitis and barrier damage was abolished by GW9662 treatment, as indicated by increased levels of LPS in the colon content and pro-inflammatory cytokines in the colonic tissue, as well as decreased expression of tight junction protein ZO-1 (Figure 6J-M). The gene discussed is TJP1; the disease is colitis.